Journal Mobile Options
Table of Contents
Vol. 50, No. 1, 2004
Issue release date: June 2004
Section title: Biological Psychiatry. Editor: J. Mendlewicz (Brussels). Original Paper
Neuropsychobiology 2004;50:57–64
(DOI:10.1159/000078225)

A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder

Montgomery S.A. · Huusom A.K.T. · Bothmer J.
aImperial College School of Medicine, London, UK; bH. Lundbeck A/S, Copenhagen, Denmark; cLundbeck GmbH & Co., Hamburg, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Biological Psychiatry. Editor: J. Mendlewicz (Brussels). Original Paper

Published online: 6/11/2004

Number of Print Pages: 8
Number of Figures: 5
Number of Tables: 3

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: http://www.karger.com/NPS

Abstract

This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder. The efficacy of escitalopram (10– 20 mg; n = 148) was similar to venlafaxine XR (75– 150 mg; n = 145), based on mean change from baseline to week 8 in Montgomery and Åsberg Depression Rating Scale total score. In ad hoc analyses, escitalopram-treated patients achieved sustained remission significantly faster than did venlafaxine-treated patients. More venlafaxine-treated patients had nausea, constipation, and increased sweating (p < 0.05). When treatment was completed after 8 weeks, significantly more venlafaxine-treated patients had discontinuation symptoms (p < 0.01). Thus escitalopram treatment was similar to venlafaxine treatment with respect to efficacy and was better tolerated by patients in primary care.


  

Author Contacts

Prof. Stuart A. Montgomery
Imperial College School of Medicine
PO Box 8751, London W13 8WH (UK)
Tel. +44 20 8997 2689, Fax +44 20 8566 7986
E-Mail stuart@samontgomery.co.uk

  

Article Information

Number of Print Pages : 8
Number of Figures : 5, Number of Tables : 3, Number of References : 33

  

Publication Details

Neuropsychobiology
Founded 1975 by J. Mendlewicz (Brussels)
Official Journal of the International Pharmaco-EEG Society (IPEG)

Vol. 50, No. 1, Year 2004 (Cover Date: Released June 2004)

Journal Editor: P. Netter, Giessen; J. Mendlewicz, Brussels; B. Saletu, Vienna
ISSN: 0302–282X (print), 1423–0224 (Online)

For additional information: http://www.karger.com/nps


Article / Publication Details

First-Page Preview
Abstract of Biological Psychiatry. Editor: J. Mendlewicz (Brussels). Original Paper

Published online: 6/11/2004

Number of Print Pages: 8
Number of Figures: 5
Number of Tables: 3

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: http://www.karger.com/NPS


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.